Regeneron Case Likely to Join Teva Pharmaceuticals’ FCA Causation Appeal
ArentFox Schiff – Given the ongoing, directly contradictory rulings from two judges in the same judicial district, as well as the current lack of a binding appellate guidance, the issue is headed to the First Circuit for a critical showdown that will have wide-ranging impact on future FCA proceedings.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.